Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10 by CheckRare Staff| Published on: Oct 8, 2026

Therapies for MCT8 Deficiency and Nephrotic Syndrome Get FDA Approval | The CheckRare Brief Ep 10 by CheckRare Staff| Published on: Oct 8, 2026 https://checkrare.com/therapies-for-mct8-deficiency-and-nephrotic-syndrome-get-fda-approval-the-checkrare-brief-ep-10/ On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It’s the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. MCT8 deficiency is a rare genetic disorder that mostly affects boys because the gene is on the X chromosome. The gene here makes a transporter protein called MCT8, which carries thyroid hormone into cells. When that transporter doesn’t work, it creates two problems. One is central, and one is peripheral. On the central side, the brain is starved of thyroid hormone, and this leads to numerous developmental concerns. On the peripheral side, excess thyroid hormone builds up in the bloodstream and can be toxic, creating chronic stress on the heart and metabolism.